Alexander Digai
Research Subjects
Alexander Digai has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ainur Tauekelova
Heart Center, Corporate Fund “University Medical Center”, Astana 010000, Kazakhstan
1 shared publication - Alexander Gulyayev
National Laboratory Astana, Center for Life Sciences, Nazarbayev University, Astana 010000, Kazakhstan
1 shared publication - Almira Manatova
Department of Scientific Management, National Research Oncology Center, Astana 020000, Kazakhstan
1 shared publication - Assel Urazbayeva
National Laboratory Astana, Nazarbayev University, Kabanbai Batyr Ave. 53, Astana Z05H0P9, Kazakhstan
1 shared publication - Assiya Maikenova
National Laboratory Astana, Center for Life Sciences, Nazarbayev University, Astana 010000, Kazakhstan
1 shared publication - Ayaulym Nurgozhina
National Laboratory Astana, Center for Life Sciences, Nazarbayev University, Astana 010000, Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 11 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8095
Cardioprotective Potential of Grape-Derived Polyphenols in Cancer Therapy-Related Cardiotoxicity
Chemotherapy-induced cardiotoxicity is a serious consequence of chemotherapy during cancer treatment that can affect any patient. The purpose of this review is to highlight the development of cardiotoxicity associated with the use of anthracyclines or trastuzumab and to examine prevention and treatment methods using polyphenols, biologically active substances that hold significant therapeutic potential. The main mechanisms of this pathology, modern biomarkers for detection, and the classification and biological activity of polyphenols are discussed. Emphasis is placed on polyphenols found in grapes and their antioxidant potential as a protector of the cardiovascular system.
- 11 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8095
Open AccessCardioprotective Potential of Grape-Derived Polyphenols in Cancer Therapy-Related Cardiotoxicity
Chemotherapy-induced cardiotoxicity is a serious consequence of chemotherapy during cancer treatment that can affect any patient. The purpose of this review is to highlight the development of cardiotoxicity associated with the use of anthracyclines or trastuzumab and to examine prevention and treatment methods using polyphenols, biologically active substances that hold significant therapeutic potential. The main mechanisms of this pathology, modern biomarkers for detection, and the classification and biological activity of polyphenols are discussed. Emphasis is placed on polyphenols found in grapes and their antioxidant potential as a protector of the cardiovascular system.
- Open Access
The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions
Pleural malignancies represent a clinically devastating group of oncological disorders, most commonly arising from metastatic disease, with lung and breast cancers being the most frequent primary sites. Malignant pleural mesothelioma is a primary malignancy of the pleura and occurs less often than metastatic pleural disease. Pleural malignancies often present with malignant pleural effusion, which typically indicates advanced-stage disease and is associated with poor overall prognosis. Treatment of pleural malignancies includes both palliative and definitive approaches. Palliative interventions primarily aim to relieve symptoms and improve quality of life. Definitive treatments include systemic chemotherapy, targeted therapy, and immunotherapy, depending on the type and molecular profile of the underlying tumor. In mesothelioma, platinum-based chemotherapy in combination with pemetrexed remains the cornerstone of treatment, while the combination of nivolumab and ipilimumab is recommended as first-line therapy for unresectable disease. For metastatic disease, systemic therapy is typically tailored to the primary tumor’s characteristics. Intrapleural administration of chemotherapeutic agents is one of the therapeutic strategies and hyperthermic intrathoracic chemotherapy and pressurized intrathoracic aerosol chemotherapy are the most recent innovations that are under active investigation. This review provides an up-to-date synthesis of systemic chemotherapy strategies for pleural malignancies, their integration with targeted and immune-based therapies, and recent advances in intrapleural chemotherapy modalities. It also explores existing knowledge gaps and outlines directions for future research and potential changes in clinical practice.
Open AccessThe Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions
Pleural malignancies represent a clinically devastating group of oncological disorders, most commonly arising from metastatic disease, with lung and breast cancers being the most frequent primary sites. Malignant pleural mesothelioma is a primary malignancy of the pleura and occurs less often than metastatic pleural disease. Pleural malignancies often present with malignant pleural effusion, which typically indicates advanced-stage disease and is associated with poor overall prognosis. Treatment of pleural malignancies includes both palliative and definitive approaches. Palliative interventions primarily aim to relieve symptoms and improve quality of life. Definitive treatments include systemic chemotherapy, targeted therapy, and immunotherapy, depending on the type and molecular profile of the underlying tumor. In mesothelioma, platinum-based chemotherapy in combination with pemetrexed remains the cornerstone of treatment, while the combination of nivolumab and ipilimumab is recommended as first-line therapy for unresectable disease. For metastatic disease, systemic therapy is typically tailored to the primary tumor’s characteristics. Intrapleural administration of chemotherapeutic agents is one of the therapeutic strategies and hyperthermic intrathoracic chemotherapy and pressurized intrathoracic aerosol chemotherapy are the most recent innovations that are under active investigation. This review provides an up-to-date synthesis of systemic chemotherapy strategies for pleural malignancies, their integration with targeted and immune-based therapies, and recent advances in intrapleural chemotherapy modalities. It also explores existing knowledge gaps and outlines directions for future research and potential changes in clinical practice.